Engineered immune cell and use thereof
US11896620B2 · kind B2 · utility
0Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 2021 |
| Grant date | Feb 13, 2024 |
| Priority date | — |
| Expiry date | May 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.